M06-890: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ST

M06-890：3 期、多中心、随机、双盲、安慰剂对照 ST

• 批准号: 7951078
• 负责人: GERALD D. WEINSTEIN
• 金额: $ 0.06万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951078
• 关键词: Chronic; Chronic small plaque psoriasis; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dose; Double-Blind Method; Effectiveness; Funding; Grant; Institution; Patients; Pharmaceutical Preparations; Phase; Placebo Control; Placebos; Psoriasis; Randomized; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the safety and effectiveness of ABT-874 in patients with moderate to severe chronic plaque psoriasis. Two different doses will be studied and compared to placebo. A placebo is an inactive substance that is given just like the active drug, but does not contain ABT-874. This study will look at how well ABT-874 treats psoriasis compared to Placebo over a 52-week period.

这个子项目是众多研究子项目之一